These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Hepatocellular Carcinoma Peritoneal Metastasis: Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Spiliotis J; Nikolaou G; Kopanakis N; Vassiliadou D; Terra A; Efstathiou E Gulf J Oncolog; 2017 May; 1(24):20-23. PubMed ID: 28797997 [TBL] [Abstract][Full Text] [Related]
63. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center. Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715 [TBL] [Abstract][Full Text] [Related]
64. Hyperthermic intraperitoneal chemotherapy (HIPEC) as adjuvant and therapeutic options for patients with advanced gastric cancer at high risk of recurrence or established peritoneal metastases: a single-centre experience. Allievi N; Bianco F; Pisano M; Montori G; Fugazzola P; Coccolini F; Lotti M; Mosconi S; Merelli B; Campanati L; Lucianetti A; Ansaloni L; Magnone S Updates Surg; 2023 Jan; 75(1):159-167. PubMed ID: 36371549 [TBL] [Abstract][Full Text] [Related]
65. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149 [TBL] [Abstract][Full Text] [Related]
66. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. Bonnot PE; Piessen G; Kepenekian V; Decullier E; Pocard M; Meunier B; Bereder JM; Abboud K; Marchal F; Quenet F; Goere D; Msika S; Arvieux C; Pirro N; Wernert R; Rat P; Gagnière J; Lefevre JH; Courvoisier T; Kianmanesh R; Vaudoyer D; Rivoire M; Meeus P; Passot G; Glehen O; J Clin Oncol; 2019 Aug; 37(23):2028-2040. PubMed ID: 31084544 [TBL] [Abstract][Full Text] [Related]
67. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? Chia CS; You B; Decullier E; Vaudoyer D; Lorimier G; Abboud K; Bereder JM; Arvieux C; Boschetti G; Glehen O; Ann Surg Oncol; 2016 Jun; 23(6):1971-9. PubMed ID: 26753751 [TBL] [Abstract][Full Text] [Related]
68. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504 [TBL] [Abstract][Full Text] [Related]
69. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases. Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066 [TBL] [Abstract][Full Text] [Related]
70. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Wu XJ; Yuan P; Li ZY; Bu ZD; Zhang LH; Wu AW; Zong XL; Li SX; Shan F; Ji X; Ren H; Ji JF Tumour Biol; 2013 Feb; 34(1):463-9. PubMed ID: 23108893 [TBL] [Abstract][Full Text] [Related]
71. Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery for gastric carcinoma at high risk of peritoneal carcinomatosis: short and long-term outcomes (GOETH STUDY)-a collaborative randomized controlled trial by ACOI, FONDAZIONE AIOM, SIC, SICE, and SICO. Di Giorgio A; Gerardi C; Abatini C; Melotti G; Bonavina L; Torri V; Santullo F; Garattini S; De Luca M; Rulli E; Rulli E; Pacelli F; Trials; 2022 Dec; 23(1):969. PubMed ID: 36457115 [TBL] [Abstract][Full Text] [Related]
72. The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases. van der Werf LR; Wassenaar E; de Niet A; Lalezari F; Braam HJ; van Ramshorst B; Nederend J; de Hingh IHJT; Kok NFM; Aalbers AGJ Eur J Surg Oncol; 2019 Mar; 45(3):376-382. PubMed ID: 30414704 [TBL] [Abstract][Full Text] [Related]
73. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes. Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834 [TBL] [Abstract][Full Text] [Related]
74. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies. Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429 [TBL] [Abstract][Full Text] [Related]
75. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center. Wu HT; Peng KW; Ji ZH; Sun JH; Zhang Q; Yang XJ; Huang CQ; Li Y Eur J Surg Oncol; 2016 Jul; 42(7):1024-34. PubMed ID: 27179924 [TBL] [Abstract][Full Text] [Related]
76. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial. van de Vlasakker VCJ; Guchelaar NAD; van den Heuvel TBM; Lurvink RJ; van Meerten E; Bax RJF; Creemers GM; van Hellemond IEG; Brandt-Kerkhof ARM; Madsen EVE; Nederend J; Koolen SLW; Nienhuijs SW; Kranenburg O; de Hingh IHJT; Verhoef C; Mathijssen RHJ; Burger JWA; ; BMJ Open; 2024 Jan; 14(1):e077667. PubMed ID: 38238055 [TBL] [Abstract][Full Text] [Related]
77. Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases. Ji ZH; Peng KW; Yu Y; Li XB; Yonemura Y; Liu Y; Sugarbaker PH; Li Y Int J Hyperthermia; 2017 Aug; 33(5):562-570. PubMed ID: 28124576 [TBL] [Abstract][Full Text] [Related]
78. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system. Naffouje SA; O'Donoghue C; Salti GI J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613 [TBL] [Abstract][Full Text] [Related]
79. Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey. Morales-Soriano R; Esteve-Pérez N; Segura-Sampedro JJ; Cascales-Campos P; Barrios P; Eur J Surg Oncol; 2018 Feb; 44(2):228-236. PubMed ID: 29242018 [TBL] [Abstract][Full Text] [Related]
80. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for endometrial cancer-derived peritoneal metastases: a systematic review. Tempfer CB; Kern P; Dogan A; Hilal Z; Rezniczek GA Clin Exp Metastasis; 2019 Aug; 36(4):321-329. PubMed ID: 31089843 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]